--- title: Preclinical Oncology Services - TD2 Precision Oncology description: TD2’s integrated suite of preclinical CRO services provides our clients with data that drives the development of new oncology therapies. image: https://td2inc.com/hubfs/Assets/Images/og-preclinical.jpg --- ×   [![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en) ![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png) [![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en) ![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png) ## Preclinical # *In Vivo* and *In Vitro* Services to Advance Your Drug Discovery TD2’s integrated suite of preclinical services provides our clients with data that drives the development of clinical strategy. From the discovery stage to NDA strategy, we offer our clients advanced solutions to move their programs forward. Our comprehensive service offerings utilized to rapidly move your treatments to the clinic include DMPK/ADME, in vitro and in vivo pharmacology, expert study design and execution. Your in vivo pharmacology studies are run in our AAALAC-accredited rodent facility with the highest regard for animal welfare. All studies are conducted with a commitment to meeting the high-quality standards you expect, and each offering is customizable to meet your unique development needs. With expert drug development insight and strategy and skilled project management, TD2 is your partner for an efficient path to the clinic. ![Preclinical Models and Services](https://td2inc.com/hs-fs/hubfs/Assets/Icon/icon-clinical-study-management.png?width=101&height=85&name=icon-clinical-study-management.png) ### PRECLINICAL ## Models and Services TD2’s service offering is consistently expanding and currently includes: **Model Systems:** - [Syngeneic Tumor Models](https://td2inc.com/syngeneic-models/?hsLang=en) - [Orthotopic Tumor Models](https://td2inc.com/orthotopic-tumor-models/?hsLang=en) - [Patient Derived Xenograft (PDX) Models](https://td2inc.com/pdx-models?hsLang=en) - [Humanized Mouse Models](https://td2inc.com/humanized-immune-checkpoint-inhibitor-mouse-models/?hsLang=en) - [Diet-Induced Obesity Tumor Model](https://td2inc.com/diet-induced-obesity-model-for-cancer-research/?hsLang=en) - [Adoptive Cell Therapy Models](https://td2inc.com/lp-car-t-study/?hsLang=en) - [Cell Line Derived Xenografts Models (CDX)](https://td2inc.com/lp-advancing-oncology-research-cdx-for-preclinical-studies/?hsLang=en) **Bioanalytical Services:** - [Flow Cytometry](https://td2inc.com/lp-flow-cytometry-services/?hsLang=en) - [Metabolomics and Proteomics Analysis](https://td2inc.com/metabolomics-proteomics-services/?hsLang=en) - [DMPK/ADME services](https://td2inc.com/lp-complete-dmpk-analysis/?hsLang=en) - Non-GLP Safety/Tolerability ***In vivo* and *In vitro* Characterization** - *In vitro* Pharmacology Assays - [*In vivo* Optical Imaging](https://td2inc.com/optical-imaging-services-for-preclinical-evaluation?hsLang=en) - Efficacy Evaluation **Therapeutic Evaluation:** - [Antibody Drug Conjugate (ADC)](https://td2inc.com/lp-advancing-adc-therapeutics-in-oncology/?hsLang=en) - Small Molecule - Cell Therapy - Checkpoint Inhibitors - mAbs - Vaccines - Gene Therapy ![Tumor Models Trusted IO Models](https://td2inc.com/hs-fs/hubfs/Assets/Images/iomodels.png?width=584&height=584&name=iomodels.png) ### Tumor Models ## Trusted IO Models At TD2, we are dedicated to providing you with the most comprehensive preclinical immuno-oncology studies possible. Our experienced team offers a broad range of human and murine tumor models that allow for the planning and execution of studies in solid or hematologic malignancies. Our syngeneic tumor models are fully characterized for gene expression, TIL baseline populations, and response to common immune checkpoint inhibitors (ICI), allowing for rapid, trusted study outcomes. These syngeneic cell lines can also be combined with our wide range of humanized immune checkpoint inhibitor mouse models to evaluate your ICI treatment. When syngeneic mouse systems are not applicable for your drug, we can employ the use of humanized mice either by engrafting with human PBMCs or other effector cells or utilizing sourced CD34+ humanized mice. TD2’s vast experience in Adoptive Cell Transfer Therapy studies in both solid and hematologic tumors is unmatched in the industry. We have the expertise to provide you with the most accurate and reliable data possible, ensuring the success of your drug development program. [Cell Therapy Models +](https://td2inc.com/lp-car-t-study/?hsLang=en) [Syngeneic Models +](https://td2inc.com/syngeneic-models/?hsLang=en) [Humanized Immune Checkpoint Inhibitor Mouse Models +](https://td2inc.com/humanized-immune-checkpoint-inhibitor-mouse-models/?hsLang=en) ### Tumor Models ## Specialized Animal Models Regardless of the development question, TD2 has the specialized model you need to move your drug forward. Clients have access to humanized models, induction models, as well as specialty surgical and orthotopic models. Since we specialize in all areas of oncology and work diligently to understand your therapeutic’s mechanism of action and match that with clinical development strategies, we are constantly working to validate new model systems that represent areas of unmet medical need. ## Glioblastoma PDX Models ** We have more than 60 first-presentation and recurrent Primary (PDX) Glioblastoma Models that include: - MOA-Based Filters using selections driven by your drug’s specific mechanism of action and subsequent interrogation - Diverse tissue types including fixed tissue for analysis of novel markers - Assessment of tumor progression as single agents and in combination with standard therapies via orthotopic primary tumor models - Well-established protocols that ensure an extremely high post-surgery survival rate - Data-rich and highly characterized models with standard of care [Specialized Glioblastoma Models +](https://td2inc.com/lp-specialized-glioblastoma-models/?hsLang=en) ## Multiple Myeloma Models ** Our Multiple Myeloma Transgenic Mouse Model is proven to improve multiple myeloma efficacy studies with more than 60 agents from Vk-Myc, a genetically engineered, clinically predictive mouse model from Dr. Leif Bersagel’s lab housed at the Mayo Clinic. ## Fibrosis Models ** Inflammation is a common factor driving many diseases, including both oncology and fibrosis. Models of fibrosis can be very useful in multiple areas, including understanding drug effects on the tumor microenvironment. Our fibrosis induction liver models include DEN, CCl4, choline-deficient high-fat diet in addition to the bleomycin lung injury model. ![Tumor Models Specialized Animal Models](https://td2inc.com/hs-fs/hubfs/Assets/Images/tumormodels.png?width=583&height=583&name=tumormodels.png) ![In Vitro Pharmacology](https://td2inc.com/hs-fs/hubfs/Assets/Images/invitropharmacology.png?width=634&height=586&name=invitropharmacology.png) ### In Vitro Pharmacology ## In vitro tools to guide your preclinical therapy. With TD2’s vast set of in vitro preclinical tools, you can explore drug effects on tumor cells, immune cells, and tumor/effector cell potentiation for earlier guidance on efficacy. Utilizing our in-house Tecan D300 digital dispenser, TD2 can ensure precise delivery of test agents giving rapid and confident data sets. When you partner with an oncology CRO like TD2, you will have access to more than 400 proof-of-concept tumor cell lines – all well-characterized – making the transition to in vivo studies seamless. In our In Vitro Pharmacology Laboratory, we execute assays that can: - Define potency on viability in a panel of cell lines - Identify sensitivity and resistance profiles - Shape in vivo proof of concept study design - Determine combination interaction outcomes with immune effector cells - Assess combination interaction with standard of care agents (Synergy studies) - Determine optimal drug sequencing ### In Vivo Pharmacology ## Support for your preclinical goals. With access to our expansive collection of human and murine tumor cell-line based models representing all of the major and many rare histologies, TD2 can assist its clients with expert selection of relevant tumor xenograft or syngeneic models tailored to your development questions in a way that will rapidly drive development of your therapy. Our in vivo efficacy studies are designed to identify, streamline, and optimize development strategies for your oncology therapeutic – including endpoints of tumor growth inhibition, tumor growth delay, imaging endpoints and biomarker analysis – and give you direction on your path to the clinic. Additional support in in vivo preclinical services includes: ## Imaging ** WHigh-tech, multi-modal AMI 1000 optimal imaging designed for powerful bioluminescence, fluorescence and X-ray ## Toxicology Assessments ** Non-GLP toxicology assessments including dose range finding, pharmacokinetic analysis, CBC and blood chemistries, and highly sophisticated histopathology services used to glean early toxicity insights ## Data Collection ** Accurate data collection and reporting using StudyLog®, our electronic data collection software that enables reliable data collection and faster analysis ## Expert Project Management ** Expert project management for efficient study execution and reliable data delivery [View Current Vivarium Monitoring Report](https://td2inc.com/vivarium-monitoring-report/?hsLang=en) ![In Vivo Pharmacology](https://td2inc.com/hs-fs/hubfs/Assets/Images/invivopharmacology.png?width=589&height=589&name=invivopharmacology.png) ## Additional Resources [![Development of a Receptor Occupancy Assay for a Therapeutic Bi-Specific Antibody](https://td2inc.com/hubfs/poster-219-thumb-2.jpg)](https://td2inc.com/poster-development-of-a-receptor-occupancy-assay-for-a-therapeutic-bi-specific-antibody?hsLang=en) Flow ## [Development of a Receptor Occupancy Assay for a Therapeutic Bi-Specific Antibody](https://td2inc.com/poster-development-of-a-receptor-occupancy-assay-for-a-therapeutic-bi-specific-antibody?hsLang=en) [![Measurement of Basophil Activation Using a Flow Cytometry Method for Applications in Clinical Research and Clinical Trials](https://td2inc.com/hubfs/poster-measurement-of-basophil-activation.jpg)](https://td2inc.com/poster-measurement-of-basophil-activation-using-a-flow-cytometry-method-for-applications-in-clinical-research-and-clinical-trials?hsLang=en) Flow ## [Measurement of Basophil Activation Using a Flow Cytometry Method for Applications in Clinical Research and Clinical Trials](https://td2inc.com/poster-measurement-of-basophil-activation-using-a-flow-cytometry-method-for-applications-in-clinical-research-and-clinical-trials?hsLang=en) [![Optimizing Specimen Stability – A Comparative Analysis of Shipping Protocols](https://td2inc.com/hubfs/white-paper-optimizing-specimen-stability-thumb.png)](https://td2inc.com/wp-optimizing-specimen-stability-a-comparative-analysis-of-shipping-protocols?hsLang=en) Flow ## [Optimizing Specimen Stability – A Comparative Analysis of Shipping Protocols](https://td2inc.com/wp-optimizing-specimen-stability-a-comparative-analysis-of-shipping-protocols?hsLang=en) [![Design and Validation of a Model of a Receptor Occupancy Assay for a New Immunotherapy in Human Whole Blood Specimens](https://td2inc.com/hubfs/flow-poster-thumb.png)](https://td2inc.com/sitc-2024-poster-design-and-validation-of-a-model-of-a-receptor-occupancy-assay?hsLang=en) Flow ## [Design and Validation of a Model of a Receptor Occupancy Assay for a New Immunotherapy in Human Whole Blood Specimens](https://td2inc.com/sitc-2024-poster-design-and-validation-of-a-model-of-a-receptor-occupancy-assay?hsLang=en) [![The Antitumor and Metabolomic Difference Between Male and Female Diet Induced Obese Mice Treated With Check Point Inhibitors](https://td2inc.com/hubfs/1364-thumb.png)](https://td2inc.com/sitc-2024-poster-1364?hsLang=en) Preclinical ## [The Antitumor and Metabolomic Difference Between Male and Female Diet Induced Obese Mice Treated With Check Point Inhibitors](https://td2inc.com/sitc-2024-poster-1364?hsLang=en) [![Comprehensive Oncology Ecosystem](https://td2inc.com/hubfs/Oncology-Ecosystem.jpeg)](https://td2inc.com/welcome-to-td2s-comprehensive-oncology-ecosystem?hsLang=en) Regulatory, Clinical, Preclinical, PK/ADME, Flow ## [Comprehensive Oncology Ecosystem](https://td2inc.com/welcome-to-td2s-comprehensive-oncology-ecosystem?hsLang=en) [![Advancing Antibody-Drug Conjugate Therapies: Key Preclinical and Regulatory Strategies for Clinical Success](https://td2inc.com/hubfs/thumb-webinar-clinical-success.png)](https://td2inc.com/lp-webinar-advancing-antibody-drug-conjugate-therapies?hsLang=en) Regulatory, Preclinical, Videos ## [Advancing Antibody-Drug Conjugate Therapies: Key Preclinical and Regulatory Strategies for Clinical Success](https://td2inc.com/lp-webinar-advancing-antibody-drug-conjugate-therapies?hsLang=en) [![Flow Cytometry-Based Receptor Occupancy Assays: Technical Challenges and Applications in Drug Development](https://td2inc.com/hubfs/flow-wp-thumb.png)](https://td2inc.com/wp-flow-cytometry-based-receptor-occupancy-assays?hsLang=en) Flow ## [Flow Cytometry-Based Receptor Occupancy Assays: Technical Challenges and Applications in Drug Development](https://td2inc.com/wp-flow-cytometry-based-receptor-occupancy-assays?hsLang=en) [![Model and Bioanalytical Services Catalog](https://td2inc.com/hubfs/services-catalog-thumb.png)](https://td2inc.com/lp-model-and-bioanalytical-services-catalog?hsLang=en) Preclinical ## [Model and Bioanalytical Services Catalog](https://td2inc.com/lp-model-and-bioanalytical-services-catalog?hsLang=en) [![Validated Tumor Cell Lines](https://td2inc.com/hubfs/Assets/Images/thumb-poc.png)](https://td2inc.com/lp-validated-tumor-cell-lines/?hsLang=en) Preclinical ## [Validated Tumor Cell Lines](https://td2inc.com/lp-validated-tumor-cell-lines/?hsLang=en) [![Epigenetic-Based Combinatorial Therapy is Synergistic in KRAS/LKB1 Mutant Non-Small Cell Lung Cancers](https://td2inc.com/hubfs/Assets/Images/6491.png)](https://td2inc.com/aacr-2024-poster-6491?hsLang=en) Preclinical, Posters and Publications ## [Epigenetic-Based Combinatorial Therapy is Synergistic in KRAS/LKB1 Mutant Non-Small Cell Lung Cancers](https://td2inc.com/aacr-2024-poster-6491?hsLang=en) [![Integrating PDX GBM In Vivo Models with Patient History and Whole Exome Sequencing: Advancing Relevance and Precision in Preclinical Studies](https://td2inc.com/hubfs/Assets/Images/6908.png)](https://td2inc.com/aacr-2024-poster-6908?hsLang=en) Preclinical, Posters and Publications ## [Integrating PDX GBM In Vivo Models with Patient History and Whole Exome Sequencing: Advancing Relevance and Precision in Preclinical Studies](https://td2inc.com/aacr-2024-poster-6908?hsLang=en) [![Flow cytometry evaluation of cell cycle arrest in A549 human non-small cell lung cancer cells and tumors following treatment with cell cycle inhibitors: A multifaceted approach to targeting cancer](https://td2inc.com/hubfs/Assets/Images/510.png)](https://td2inc.com/aacr-2024-poster-510?hsLang=en) Flow ## [Flow cytometry evaluation of cell cycle arrest in A549 human non-small cell lung cancer cells and tumors following treatment with cell cycle inhibitors: A multifaceted approach to targeting cancer](https://td2inc.com/aacr-2024-poster-510?hsLang=en) [![Immunophenotyping Pig Immune Cells by Flow Cytometry: A Powerful Tool for Pharmacology and Toxicology Studies](https://td2inc.com/hubfs/Assets/Images/flow-thumb-9.png)](https://td2inc.com/lp-fcsl-poster-2024-immunophenotyping-pig-immune-cells-by-flow-cytometry-a-powerful-tool-for-pharmacology-and-toxicology-studies/?hsLang=en) Flow ## [Immunophenotyping Pig Immune Cells by Flow Cytometry: A Powerful Tool for Pharmacology and Toxicology Studies](https://td2inc.com/lp-fcsl-poster-2024-immunophenotyping-pig-immune-cells-by-flow-cytometry-a-powerful-tool-for-pharmacology-and-toxicology-studies/?hsLang=en) [![Flow Cytometry Application in Water Microbiology: Testing Bacterial Content in Water](https://td2inc.com/hubfs/Assets/Images/flow-thumb-8.png)](https://td2inc.com/lp-fcsl-poster-2024-flow-cytometry-application-in-water-microbiology/?hsLang=en) Flow ## [Flow Cytometry Application in Water Microbiology: Testing Bacterial Content in Water](https://td2inc.com/lp-fcsl-poster-2024-flow-cytometry-application-in-water-microbiology/?hsLang=en) [![Flow Cytometry Processing and Analysis of Tumor Specimens: Testing Viability and Staining Post Shipping](https://td2inc.com/hubfs/Assets/Images/flow-thumb-7.png)](https://td2inc.com/lp-fcsl-poster-2024-flow-cytometry-processing-and-analysis-of-tumor-specimens/?hsLang=en) Flow ## [Flow Cytometry Processing and Analysis of Tumor Specimens: Testing Viability and Staining Post Shipping](https://td2inc.com/lp-fcsl-poster-2024-flow-cytometry-processing-and-analysis-of-tumor-specimens/?hsLang=en) [![Flow Cytometry Based Assessment of Innate Immune Function Using Phagocytosis and Reactive Oxygen Species Measurement](https://td2inc.com/hubfs/Assets/Images/flow-thumb-6.png)](https://td2inc.com/lp-fcsl-poster-2024-flow-cytometry-based-assessment-of-innate-immune-function-using-phagocytosis-and-reactive-oxygen-species-measurement/?hsLang=en) Flow ## [Flow Cytometry Based Assessment of Innate Immune Function Using Phagocytosis and Reactive Oxygen Species Measurement](https://td2inc.com/lp-fcsl-poster-2024-flow-cytometry-based-assessment-of-innate-immune-function-using-phagocytosis-and-reactive-oxygen-species-measurement/?hsLang=en) [![Measurement of Cytokine mRNA Expression by Flow Cytometry Using the Branched DNA Technology](https://td2inc.com/hubfs/Assets/Images/flow-thumb-5.png)](https://td2inc.com/lp-fcsl-poster-2024-measurement-of-cytokine-mrna-expression/?hsLang=en) Flow ## [Measurement of Cytokine mRNA Expression by Flow Cytometry Using the Branched DNA Technology](https://td2inc.com/lp-fcsl-poster-2024-measurement-of-cytokine-mrna-expression/?hsLang=en) [![10-Color Flow Cytometry Panels for the Evaluation of T Cell Subsets Such as TH Subsets, T Cell Activation, and T Regulatory Cells for Application in Clinical Trials](https://td2inc.com/hubfs/Assets/Images/flow-thumb-4.png)](https://td2inc.com/lp-fcsl-poster-2024-10-color-flow-cytometry-panels-for-the-evaluation-of-t-cell-subsets/?hsLang=en) Flow ## [10-Color Flow Cytometry Panels for the Evaluation of T Cell Subsets Such as TH Subsets, T Cell Activation, and T Regulatory Cells for Application in Clinical Trials](https://td2inc.com/lp-fcsl-poster-2024-10-color-flow-cytometry-panels-for-the-evaluation-of-t-cell-subsets/?hsLang=en) [![The Advantages of Fluorescent Barcoding of Human Cells Using Flow Cytometry for High Throughput Testing With an Application For Human Clinical Trials](https://td2inc.com/hubfs/Assets/Images/flow-thumb-3.png)](https://td2inc.com/lp-fcsl-poster-2024-the-advantages-of-fluorescent-barcoding-of-human-cells-using-flow-cytometry/?hsLang=en) Flow ## [The Advantages of Fluorescent Barcoding of Human Cells Using Flow Cytometry for High Throughput Testing With an Application For Human Clinical Trials](https://td2inc.com/lp-fcsl-poster-2024-the-advantages-of-fluorescent-barcoding-of-human-cells-using-flow-cytometry/?hsLang=en) [![The Activation Profiling of Stat in Human Whole Blood Samples By Flow Cytometry With an Application for Human Clinical Trials](https://td2inc.com/hubfs/Assets/Images/flow-poster-2.png)](https://td2inc.com/lp-fcsl-poster-2024-the-activation-profiling-of-stat-in-human-whole-blood-samples/?hsLang=en) Flow ## [The Activation Profiling of Stat in Human Whole Blood Samples By Flow Cytometry With an Application for Human Clinical Trials](https://td2inc.com/lp-fcsl-poster-2024-the-activation-profiling-of-stat-in-human-whole-blood-samples/?hsLang=en) [![Design and Validation of a Model of a Receptor Occupancy Assay for a New Immunotherapy in Human Whole Blood Specimens](https://td2inc.com/hubfs/Assets/Images/flow-poster-1.png)](https://td2inc.com/lp-fcsl-poster-2024-design-and-validation-of-a-model-of-a-receptor-occupancy-assay/?hsLang=en) Flow ## [Design and Validation of a Model of a Receptor Occupancy Assay for a New Immunotherapy in Human Whole Blood Specimens](https://td2inc.com/lp-fcsl-poster-2024-design-and-validation-of-a-model-of-a-receptor-occupancy-assay/?hsLang=en) [![The Importance of Metabolic and Proteomic Analyses in Identifying Treatment Pathways for Cancer Patients](https://td2inc.com/hubfs/podcast-thumb.png)](https://td2inc.com/lp-podcast-the-importance-of-metabolic-and-proteomic-analyses-in-identifying-treatment-pathways-for-cancer-patients/?hsLang=en) Preclinical ## [The Importance of Metabolic and Proteomic Analyses in Identifying Treatment Pathways for Cancer Patients](https://td2inc.com/lp-podcast-the-importance-of-metabolic-and-proteomic-analyses-in-identifying-treatment-pathways-for-cancer-patients/?hsLang=en) [![Advancing Preclinical Cancer Research Through Metabolomics: Key Strategies for Biomarker Identification and Drug-Target Analysis in Immuno-Oncology](https://td2inc.com/hubfs/Assets/Images/global-metabolomics.png)](https://blog.td2inc.com/advancing-preclinical-cancer-research-through-metabolomics?hsLang=en) Preclinical ## [Advancing Preclinical Cancer Research Through Metabolomics: Key Strategies for Biomarker Identification and Drug-Target Analysis in Immuno-Oncology](https://blog.td2inc.com/advancing-preclinical-cancer-research-through-metabolomics?hsLang=en) [![E-Book: Using the Diet Induced Obese Mouse Model for Modern Cancer Research](https://td2inc.com/hubfs/thubm-ebook-cover.jpeg)](https://td2inc.com/ebook-using-the-diet-induced-obese-mouse-model-for-modern-cancer-research/?hsLang=en) Preclinical, Posters and Publications ## [E-Book: Using the Diet Induced Obese Mouse Model for Modern Cancer Research](https://td2inc.com/ebook-using-the-diet-induced-obese-mouse-model-for-modern-cancer-research/?hsLang=en) [![A Dual-specific Inhibitor of Rock/Aurk, RR-1752, for Primary Myelofibrosis](https://td2inc.com/hubfs/ash-poster-thumb-2.png)](https://td2inc.com/lp-ash-2023/?hsLang=en) Preclinical, Posters and Publications ## [A Dual-specific Inhibitor of Rock/Aurk, RR-1752, for Primary Myelofibrosis](https://td2inc.com/lp-ash-2023/?hsLang=en) [![Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers](https://td2inc.com/hubfs/inhibition-of-hdac3.jpeg)](https://td2inc.com/lp-inhibition-of-hdac3-induces-brcaness-and-potent-synergy/?hsLang=en) Preclinical, Posters and Publications ## [Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers](https://td2inc.com/lp-inhibition-of-hdac3-induces-brcaness-and-potent-synergy/?hsLang=en) [![Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to Induce Tumor Regressions](https://td2inc.com/hubfs/selective-hdac6-inhibition.jpeg)](https://td2inc.com/lp-selective-hdac6-inhibition-by-gb-1101-revokes-tumor-immune-privilege-and-synergizes/?hsLang=en) Preclinical, Posters and Publications ## [Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to Induce Tumor Regressions](https://td2inc.com/lp-selective-hdac6-inhibition-by-gb-1101-revokes-tumor-immune-privilege-and-synergizes/?hsLang=en) [![SITC 2023 Poster: Antitumor and metabolomic evaluation of immune checkpoint inhibition in diet-induced obese mice](https://td2inc.com/hubfs/thumb-abstract8.png)](https://td2inc.com/lp-sitc-2023-poster/?hsLang=en) Preclinical, Posters and Publications ## [SITC 2023 Poster: Antitumor and metabolomic evaluation of immune checkpoint inhibition in diet-induced obese mice](https://td2inc.com/lp-sitc-2023-poster/?hsLang=en) [![Orthotopic vs. Subcutaneous: Unpacking the Strengths and Limitations of Tumor Model Implantation Sites](https://td2inc.com/hubfs/vs-mice.png)](https://blog.td2inc.com/orthotopic-vs.-subcutaneous?hsLang=en) Preclinical ## [Orthotopic vs. Subcutaneous: Unpacking the Strengths and Limitations of Tumor Model Implantation Sites](https://blog.td2inc.com/orthotopic-vs.-subcutaneous?hsLang=en) [![Unveiling the Potential: 5 Ways DIO Mice Enhance Immuno-Oncology Discoveries](https://td2inc.com/hubfs/Assets/Images/dio-for-io-studies.png)](https://blog.td2inc.com/5-ways-dio-mice-enhance-immuno-oncology-discoveries?hsLang=en) Preclinical ## [Unveiling the Potential: 5 Ways DIO Mice Enhance Immuno-Oncology Discoveries](https://blog.td2inc.com/5-ways-dio-mice-enhance-immuno-oncology-discoveries?hsLang=en) [![Genetically Engineered Humanized Mouse Models: A Critical Tool for Studying Immunotherapy Drugs](https://td2inc.com/hubfs/Assets/Images/og-pk-adme.jpg)](https://blog.td2inc.com/genetically-engineered-humanized-mouse-models?hsLang=en) Preclinical ## [Genetically Engineered Humanized Mouse Models: A Critical Tool for Studying Immunotherapy Drugs](https://blog.td2inc.com/genetically-engineered-humanized-mouse-models?hsLang=en) [![Diet-Induced Obesity Tumor Models for Cancer Studies](https://td2inc.com/hubfs/systemic-metabolism.jpg)](https://blog.td2inc.com/diet-induced-obesity-tumor-models-for-cancer-studies?hsLang=en) Preclinical ## [Diet-Induced Obesity Tumor Models for Cancer Studies](https://blog.td2inc.com/diet-induced-obesity-tumor-models-for-cancer-studies?hsLang=en) [![Metabolomics Sample Data Analysis Report](https://td2inc.com/hubfs/report-thumb.jpeg)](https://td2inc.com/metabolomics-sample-data-analysis-report/?hsLang=en) Preclinical, Posters and Publications ## [Metabolomics Sample Data Analysis Report](https://td2inc.com/metabolomics-sample-data-analysis-report/?hsLang=en) [![Antitumor and metabolomic evaluation of immune checkpoint inhibition in diet-induced obese mice](https://td2inc.com/hubfs/thumb-lb343.jpeg)](https://td2inc.com/aacr-2023/?hsLang=en) Preclinical, Posters and Publications ## [Antitumor and metabolomic evaluation of immune checkpoint inhibition in diet-induced obese mice](https://td2inc.com/aacr-2023/?hsLang=en) [![Leading the way in defining a new Immunotherapy Response Score (IRS) to predict checkpoint inhibitor benefit](https://td2inc.com/hubfs/pd-l1-graphic.png)](https://td2inc.com/lp-publication-development-and-validation-of-an-integrative-pan-solid-tumor-predictor-of-pd-1-pd-l1-blockade-benefit/?hsLang=en) Clinical, Preclinical, Posters and Publications ## [Leading the way in defining a new Immunotherapy Response Score (IRS) to predict checkpoint inhibitor benefit](https://td2inc.com/lp-publication-development-and-validation-of-an-integrative-pan-solid-tumor-predictor-of-pd-1-pd-l1-blockade-benefit/?hsLang=en) [![The Dynamic Trial Design](https://td2inc.com/hubfs/thumb-the-dynamic-trial-design.jpeg)](https://td2inc.com/hubfs/Assets/Videos/td2-webinar.mp4?hsLang=en) Preclinical, Webinars ## [The Dynamic Trial Design](https://td2inc.com/hubfs/Assets/Videos/td2-webinar.mp4?hsLang=en) [![Checkpoint inhibitors: the gut microbiome’s role in anti-tumor response](https://td2inc.com/hubfs/thumb-checkpoint-inhibitors.jpeg)](https://td2inc.com/lp-webinar-checkpoint-inhibitors/?hsLang=en) Preclinical, Webinars ## [Checkpoint inhibitors: the gut microbiome’s role in anti-tumor response](https://td2inc.com/lp-webinar-checkpoint-inhibitors/?hsLang=en) [![Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers](https://td2inc.com/hubfs/Assets/Images/thumb-poster-inhibition-of-hdac3.jpg)](https://td2inc.com/hubfs/Assets/PDF-DOCS/Abstract-2607_GB-3103-Poster-2022-Final.pdf?hsLang=en) Preclinical, Posters and Publications ## [Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers](https://td2inc.com/hubfs/Assets/PDF-DOCS/Abstract-2607_GB-3103-Poster-2022-Final.pdf?hsLang=en) [![Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to…](https://td2inc.com/hubfs/Assets/Images/thumb-poster-selective-hdac6-inhibition.jpg)](https://td2inc.com/hubfs/Assets/PDF-DOCS/Abstract-1359_GB-1101-Poster-2022-Final.pdf?hsLang=en) Preclinical, Posters and Publications ## [Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to…](https://td2inc.com/hubfs/Assets/PDF-DOCS/Abstract-1359_GB-1101-Poster-2022-Final.pdf?hsLang=en) [![Exploring the Effects of Microbiome in Precision Oncology Therapeutic Development](https://td2inc.com/hubfs/Assets/Images/thumb-wp-exploring-the-effects-of-microbiome.jpg)](https://td2inc.com/lp-white-paper-exploring-the-effects-of-microbiome-in-precision-oncology-therapeutic-development/?hsLang=en) Preclinical, White Papers ## [Exploring the Effects of Microbiome in Precision Oncology Therapeutic Development](https://td2inc.com/lp-white-paper-exploring-the-effects-of-microbiome-in-precision-oncology-therapeutic-development/?hsLang=en) [![Many Drugs Don’t Move Past Phase I. Will Yours?](https://td2inc.com/hubfs/Assets/Images/past-phase-1.png)](https://td2inc.com/many-drugs-dont-move-past-phase-i-will-yours/?hsLang=en) Preclinical, White Papers ## [Many Drugs Don’t Move Past Phase I. Will Yours?](https://td2inc.com/many-drugs-dont-move-past-phase-i-will-yours/?hsLang=en) Preclinical, White Papers ## [CAR T-Cell Therapy: Revolutionizing Cancer Treatment](https://td2inc.com/hubfs/Assets/PDF-DOCS/TD2_CAR_T_Cell_October-1.pdf?hsLang=en) [![6 Signs You Need a New CRO for Your Preclinical Research](https://td2inc.com/hubfs/Assets/Images/6-signs.png)](https://td2inc.com/6-signs-you-need-a-new-cro-for-your-preclinical-research/?hsLang=en) Preclinical, White Papers ## [6 Signs You Need a New CRO for Your Preclinical Research](https://td2inc.com/6-signs-you-need-a-new-cro-for-your-preclinical-research/?hsLang=en) Load More ## GET STARTED ## Have questions about how TD2 can assist with your preclinical needs? We’re an oncology CRO that keeps the bottom line in mind – getting your treatment to those who need it most in the safest, most efficient way possible. [Get Started Now](https://td2inc.com/contact-us/?hsLang=en) [![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/td2-logo.png?width=160&name=td2-logo.png)](https://td2inc.com/?hsLang=en) Office 13208 E. Shea Blvd, Suite 100 Scottsdale, AZ 85259 Phone (602) 358-8300 Connect with us - - ![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/Assets/Logo/acclac-logo.png?width=139&name=acclac-logo.png) © 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)